Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects
Status:
Completed
Trial end date:
2010-09-18
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety and tolerability of SRT2104
(0.25, 0.5, 1.0, and 2.0 g/day) in type 2 diabetic subjects when administered once daily for
28 consecutive days, and to characterize the pharmacokinetic profile of SRT2104 after a
single dose and multiple administrations in type 2 diabetic subjects.
The secondary purpose of this study is to determine the effect of SRT2104 (0.25, 0.5, 1.0,
and 2.0 g/day) when administered once daily for 28 consecutive days on fasting blood glucose
and insulin and post-prandial blood glucose and insulin in type 2 diabetic subjects.